This is an HTML version of an attachment to the Freedom of Information request 'Industry, vaccines and patents (DG SANTE)'.

From:
SANTE)
To:
 (SANTE)
Subject:
FW: EFPIA COVID-19 Situational assessment to 29 January 2021
Date:
mardi 13 avril 2021 10:06:14
Attachments:
COVID-19 EFPIA&VE Situational Assessment 29 January 2021.v02docx.docx
From: 
@efpia.eu> 
Sent: Friday, January 29, 2021 3:29 PM
To: 
 (EMA) <
@ema.europa.eu>; 
EMA) <
@ema.europa.eu>
Cc: Industry <xxxxxxxx@xxx.xxxxxx.xx>; 
 (EMA)
@ema.europa.eu>; 
 (EMA)
@ema.europa.eu>; RYS Andrzej Jan (SANTE)
@ec.europa.eu>; 
SANTE)
<
@ec.europa.eu>; 
<
@efpia.eu>; 
 
@efpia.eu>;
@efpia.eu>; 
@emea.europa.eu;
KYRIAKIDES Stella (CAB-KYRIAKIDES) 
@ec.europa.eu>;
BRETON Thierry (CAB-BRETON) 
@ec.europa.eu>; LENARCIC
Janez (CAB-LENARCIC) <
@ec.europa.eu>; 
@merck.com>;
@astrazeneca.com>; 
@pfizer.com>;
@vaccineseurope.eu>; 
@gsk.com>; GALLINA Sandra (SANTE)
@ec.europa.eu>; 
(CAB-KYRIAKIDES)
@ec.europa.eu>; 
@efpia.eu>
Subject: EFPIA COVID-19 Situational assessment to 29 January 2021
 
Dear 
, dear 
Following your email of 25 January, please find attached, the brief summary of the
information we collected from EFPIA and Vaccines Europe member companies on the
supply of medicines.
 
As in the past, as we consider that the contents of the attached briefing is highly relevant to
the Commission's work, I hope you won't mind if I took the initiative to copy this mail to the
Commissioners and to DG SANTE colleagues.
Please do not hesitate to reach out if you have any questions.
Best wishes,
 
 
EFPIA - European Federation of Pharmaceutical Industries and Associations
Leopold Plaza Building
Rue du TrĂ´ne 108


B-1050 Bruxelles
Tel: +3226262555 (Switchboard)
Email: 
@efpia.eu
www.efpia.eu
For more information related to COVID-19 see:
https://efpia.eu/news-events/the-efpia-view/statements-press-
releases/european-pharmaceutical-industry-response-to-
coronavirus/